GEMAYEL GEORGES 4
4 · SUPERNUS PHARMACEUTICALS, INC. · Filed Nov 8, 2024
Insider Transaction Report
Form 4
GEMAYEL GEORGES
Director
Transactions
- Exercise/Conversion
Common Stock
2024-11-07$11.46/sh+14,213$162,881→ 27,528 total - Sale
Common Stock
2024-11-07$36.62/sh−14,213$520,480→ 13,315 total - Exercise/Conversion
Director Stock Option (Right to Buy)
2024-11-07−14,213→ 10,787 totalExercise: $11.46From: 2016-03-23Exp: 2025-03-23→ Common Stock (14,213 underlying)
Footnotes (2)
- [F1]The Reporting Person exercised the options indicated herein and sold the underlying shares prior to the expiration of such options on March 23, 2025.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.50 to $36.89. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.